Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A

27 Oct 2010

Abstract excerpt

DEB025/Debio 025 (Alisporivir) is a cyclophilin (Cyp)-binding molecule with potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo. It is currently being evaluated in phase II clinical trials. DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for HCV replication. Here we report that it was very difficult to select resistant replicons (genotype 1b) to DEB025,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Hepatitis C virus research
Share to Signaling Pathways in Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21060866
DOI: 10.1371/journal.pone.0013687

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5APMID 21060866Read ↗

Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.Semantic proximity Read ↗

A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.Semantic proximity Read ↗

Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.Semantic proximity Read ↗

Identification of cellular and viral factors related to anti‐hepatitis C virus activity of cyclophilin inhibitorSemantic proximity Read ↗

Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B.Semantic proximity Read ↗

A conserved tandem cyclophilin-binding site in hepatitis C virus nonstructural protein 5A regulates Alisporivir susceptibility.Semantic proximity Read ↗

Mechanism of Resistance of Hepatitis C Virus Replicons to Structurally Distinct Cyclophilin InhibitorsSemantic proximity Read ↗

Hepatitis E virus genome replication is independent of cyclophilins A and BSemantic proximity Read ↗

Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins.Semantic proximity Read ↗

Discovery and Development of Hepatitis C Virus NS5A Replication Complex InhibitorsSemantic proximity Read ↗

HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase.Semantic proximity Read ↗

Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.